Minneapolis-based NeoChord develops technology for the delivery of artificial chords to treat mitral valve regurgitation. In the role, Berg oversees the clinical and commercial programs for the transeptal and transapical repair of damaged mitral valve chords.
The company’s DS1000 transapical (TA) chord repair system holds commercial marketing authorization in Europe. Its use spans the placement of more than 5,000 successful neochordae in more than 2,000 patients. The company’s NeXus transseptal (TS) chord repair system incorporates the same proprietary, suture-based anchor elements as DS1000. It’s currently in feasibility clinical trials.
Taking over the oversight of these products, Berg brings with him significant medtech experience over more than 30 years. He most recently serv…